ESL Trust Services’s Royalty Pharma RPRX Stock Holding History

ESL Trust Services’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-28	Closed	-$988	–	313
2025 Q3	$988	Buy	+28	New	+$1.01K	﹤0.01%	283

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ESL Trust Services's RPRX Position: Q4 2025 in Review

ESL Trust Services sold out of Royalty Pharma (RPRX) in Q4 2025, closing a stake of 28 shares — an estimated $988 sold.

ESL Trust Services first reported a position in RPRX in Q3 2025 and held it in 1 quarter. The position peaked at $988 in Q3 2025. 540 funds tracked by Wall St. Rank hold RPRX as of Q4 2025.

ESL Trust Services reported no remaining Royalty Pharma position as of Q4 2025 after selling out during the quarter.
ESL Trust Services sold 28 Royalty Pharma shares in Q4 2025, an estimated $988.
ESL Trust Services first reported a position in Royalty Pharma in Q3 2025 and held it in 1 quarter.
ESL Trust Services's Royalty Pharma position peaked at $988 in Q3 2025.
540 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2025.

Based on ESL Trust Services's 13F filing for Q4 2025, filed 10 Feb 2026.